Anti-TNF agent etanercept augments UV-induced skin cancer development in SKH-1 mice(dagger)

Basit Öğe Kaydı
dc.contributor.authorÇalışkan, Ercan
dc.contributor.authorGamsızkan, Mehmet
dc.contributor.authorYürekli, Aslan
dc.contributor.authorBotsalı, Ayşenur
dc.contributor.authorKabalar, Mehmet Eşref
dc.contributor.authorDemiriz, Murat
dc.contributor.authorTunca, Mustafa
dc.date.accessioned2020-04-30T22:39:30Z
dc.date.available2020-04-30T22:39:30Z
dc.date.issued2019
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionBotsali, Aysenur/0000-0001-9431-2125; Yurekli, Aslan/0000-0003-2812-2133en_US
dc.descriptionWOS: 000505907900001en_US
dc.descriptionPubMed: 31868056en_US
dc.description.abstractBackground: Despite being employed in the treatment of inflammatory disorders for more than 20 years all over the world, data regarding photocarcinogenic risks of anti-TNF agents is scarce. Objective: To assess photocarcinogenic potential of anti-TNF agents. Methods: This was a placebo controlled, split-body (UVB-treated versus -untreated) study on mice. Treatment groups were infliximab (n = 11), etanercept (n = 11), cyclosporine (n = 11) and vehicle control (n = 11). Agents were introduced on the 10th week of phototherapy and continued through 24th week. The macroscopic, histological and immunohistochemical analysis of test sites were carried out. Results: Overall 132 tumors were detected on test sites. All of these tumors developed on UV-exposed sides. Histologic examination of these tumors was compatible with keratinocytic neoplasia in 128, mastocytosis in 3, epidermal cyst in 1. Median tumor burden in the UVB exposed areas for ETN, IFX, CYC, and control groups were 14.91, 10.20, 6.28, and 3.14 cm(2), respectively. ETN group demonstrated both higher tumor burden and keratinocytic neoplasia numbers than controls (p = .03, p = .025). Although there were 1.8 and 1.7 times more keratinocytic neoplasms in IFX and CYC groups compared to controls, these differences didn't reach statistically significant levels (p = .14; p = .19). Conclusion: This study points out to a significant photocarcinogenic potential of anti-TNF agent etanercept.en_US
dc.identifier.doi10.1080/09546634.2019.1708851en_US
dc.identifier.issn0954-6634
dc.identifier.issn1471-1753
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1080/09546634.2019.1708851
dc.identifier.urihttps://hdl.handle.net/20.500.12684/2745
dc.identifier.wosWOS:000505907900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal Of Dermatological Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPhotocarcinogenesisen_US
dc.subjectcyclosporineen_US
dc.subjectpsoriasisen_US
dc.subjectimmunosuppressionen_US
dc.titleAnti-TNF agent etanercept augments UV-induced skin cancer development in SKH-1 mice(dagger)en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
2745.pdf
Boyut:
679.02 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu